Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
American Society of Clinical OncologyPublished: September 29, 2023
- Key Points
- Treatment
- General Recommendations for G1–G3 GEP-NETs
- Systemic Therapy for Metastatic G1–G2 Gastrointestinal NETs (GI-NETs)
- First-line Systemic Therapy for G1–G2 GI-NETs
- Second- or Later-line Systemic Therapy for G1–G2 GI-NETs
- Systemic Therapy for Metastatic G1–G2 Pancreatic NETS (panNETs)
- First-line Systemic Therapy for G1–G2 panNETs
- Second- or Later-line Systemic Therapy for G1–G2 panNETs
- Systemic Therapy for G3 GEP-NETs
- Table
- WHO Classification and Grading Criteria for Welldifferentiated NETs of the GI Tract and Pancreas
- Algorithm
- Systemic Therapy for Tumor Control in Well-differentiated GEP-NETs
Also Found In
You rely on Guideline Central for transparency
Guideline Central and select third party use “cookies” on this website to enhance the user experience.
This technology helps us gather statistical and analytical information to optimize the relevant content for you.
The user also has the option to opt-out which may have an effect on the browsing experience.